CD8-Positive T-Lymphocytes
"CD8-Positive T-Lymphocytes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A critical subpopulation of regulatory T-lymphocytes involved in MHC Class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-LYMPHOCYTES, CYTOTOXIC) and CD8+ suppressor T-lymphocytes.
| Descriptor ID |
D018414
|
| MeSH Number(s) |
A11.118.637.555.567.569.220 A15.145.229.637.555.567.569.220 A15.382.490.555.567.569.220
|
| Concept/Terms |
CD8-Positive T-Lymphocytes- CD8-Positive T-Lymphocytes
- CD8 Positive T Lymphocytes
- CD8-Positive T-Lymphocyte
- T-Lymphocyte, CD8-Positive
- T-Lymphocytes, CD8-Positive
- T8 Lymphocytes
- Lymphocyte, T8
- Lymphocytes, T8
- T8 Lymphocyte
- T8 Cells
- Cell, T8
- Cells, T8
- T8 Cell
- CD8-Positive Lymphocytes
- CD8 Positive Lymphocytes
- CD8-Positive Lymphocyte
- Lymphocyte, CD8-Positive
- Lymphocytes, CD8-Positive
Suppressor T-Lymphocytes, CD8-Positive- Suppressor T-Lymphocytes, CD8-Positive
- CD8-Positive Suppressor T-Lymphocyte
- CD8-Positive Suppressor T-Lymphocytes
- Suppressor T Lymphocytes, CD8 Positive
- Suppressor T-Lymphocyte, CD8-Positive
- T-Lymphocyte, CD8-Positive Suppressor
- T-Lymphocytes, CD8-Positive Suppressor
- Suppressor T-Cells, CD8-Positive
- CD8-Positive Suppressor T-Cell
- CD8-Positive Suppressor T-Cells
- Suppressor T Cells, CD8 Positive
- Suppressor T-Cell, CD8-Positive
- T-Cell, CD8-Positive Suppressor
- T-Cells, CD8-Positive Suppressor
|
Below are MeSH descriptors whose meaning is more general than "CD8-Positive T-Lymphocytes".
Below are MeSH descriptors whose meaning is more specific than "CD8-Positive T-Lymphocytes".
This graph shows the total number of publications written about "CD8-Positive T-Lymphocytes" by people in this website by year, and whether "CD8-Positive T-Lymphocytes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 0 | 2 |
| 1996 | 0 | 1 | 1 |
| 1997 | 1 | 1 | 2 |
| 1999 | 1 | 1 | 2 |
| 2000 | 2 | 0 | 2 |
| 2001 | 1 | 3 | 4 |
| 2002 | 3 | 2 | 5 |
| 2003 | 2 | 3 | 5 |
| 2004 | 7 | 4 | 11 |
| 2005 | 8 | 1 | 9 |
| 2006 | 3 | 5 | 8 |
| 2007 | 1 | 1 | 2 |
| 2008 | 6 | 4 | 10 |
| 2009 | 4 | 4 | 8 |
| 2010 | 6 | 8 | 14 |
| 2011 | 1 | 6 | 7 |
| 2012 | 3 | 6 | 9 |
| 2013 | 5 | 1 | 6 |
| 2014 | 9 | 2 | 11 |
| 2015 | 3 | 2 | 5 |
| 2016 | 5 | 3 | 8 |
| 2017 | 94 | 67 | 161 |
| 2018 | 94 | 54 | 148 |
| 2019 | 43 | 41 | 84 |
| 2020 | 33 | 50 | 83 |
| 2021 | 51 | 53 | 104 |
To return to the timeline, click here.
Below are the most recent publications written about "CD8-Positive T-Lymphocytes" by people in Profiles.
-
Are the Healthy Vulnerable? Cytomegalovirus Seropositivity in Healthy Adults Is Associated With Accelerated Epigenetic Age and Immune Dysregulation. J Infect Dis. 2022 02 01; 225(3):443-452.
-
CD8+PD-L1+CXCR3+ polyfunctional T cell abundances are associated with survival in critical SARS-CoV-2-infected patients. JCI Insight. 2021 09 22; 6(18).
-
Large-Scale Identification of T-Cell Epitopes Derived From Severe Acute Respiratory Syndrome Coronavirus 2 for the Development of Peptide Vaccines Against Coronavirus Disease 2019. J Infect Dis. 2021 09 17; 224(6):956-966.
-
Durable tracking anti-SARS-CoV-2 antibodies in cancer patients recovered from COVID-19. Sci Rep. 2021 08 30; 11(1):17381.
-
Meta-analysis of single-cell RNA-seq data reveals phenotypic switching of immune cells in severe COVID-19 patients. Comput Biol Med. 2021 10; 137:104792.
-
Hemophagocytic lymphohistiocytosis following ChAdOx1 nCov-19 vaccination. J Med Virol. 2022 01; 94(1):14-16.
-
Human small intestinal infection by SARS-CoV-2 is characterized by a mucosal infiltration with activated CD8+ T cells. Mucosal Immunol. 2021 11; 14(6):1381-1392.
-
Activation or exhaustion of CD8+ T cells in patients with COVID-19. Cell Mol Immunol. 2021 10; 18(10):2325-2333.
-
Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection. Sci Adv. 2021 08; 7(34).
-
Optimization of antigen-specific CD8+ TÂ cell activation conditions for infectious diseases including COVID-19. STAR Protoc. 2021 09 17; 2(3):100789.